{"id":165,"date":"2022-10-10T01:45:30","date_gmt":"2022-10-10T01:45:30","guid":{"rendered":"https:\/\/mrna.creative-biolabs.com\/blog\/?p=165"},"modified":"2022-10-10T01:45:30","modified_gmt":"2022-10-10T01:45:30","slug":"biontechs-car-t-carva-therapy-has-reduced-clinical-effects-on-solid-tumors-but-remarkable-effects-on-testicular-cancer","status":"publish","type":"post","link":"https:\/\/mrna.creative-biolabs.com\/blog\/biontechs-car-t-carva-therapy-has-reduced-clinical-effects-on-solid-tumors-but-remarkable-effects-on-testicular-cancer\/","title":{"rendered":"BioNTech’s CAR-T + CARVa Therapy has Reduced Clinical Effects on Solid Tumors But Remarkable Effects on Testicular Cancer"},"content":{"rendered":"

At the 2022 annual meeting of the American Association for Cancer Research (AACR), BioNTech released its phase 1 clinical data of CAR-T + CARVac in the treatment of Claudin6 (CLDN6) positive solid tumors (testicular cancer, ovarian cancer, etc.). Among the 14 patients who can evaluate the efficacy, the objective remission rate was 43%, and the disease control rate was 86%, showing good safety and encouraging preliminary therapeutic effects. This is also the first human trial to improve the expansion and persistence of CAR-T cells with mRNA vaccines.<\/span><\/p>\n

However, at the latest European Society of Oncology (ESCO), BioNTech presented the new clinical trial results, which showed that of the 21 patients currently assessable, the objective remission rate dropped to 33% and the disease control rate dropped to 67%.<\/span><\/p>\n

CAR T-cell therapy has completely changed the treatment choice of hematological malignant tumors, but its application in solid tumors has always been a challenge. One of the major limitations is that most therapeutic targets on solid tumors are also expressed in small amounts in normal cells, which makes it difficult to target CAR T-cell s specifically to tumor cells without harming normal cells. In addition, the inhibitory tumor microenvironment of solid tumor makes it difficult for CAR T-cell s to last and CAR T-cell s to penetrate solid tumor.<\/span><\/p>\n

This open-label, multicenter human clinical trial aims to evaluate the safety and preliminary efficacy of CLDN6-CAR-T cell therapy (BNT211). CLDN6 is a tumor-specific antigen widely expressed in a variety of solid tumors but silenced in normal adult tissues.<\/span><\/p>\n

In January 2020, the preclinical study published by BioNTech in Science showed that the combination of CLDN-CAR-T and mRNA vaccine<\/a><\/strong><\/span> encoding CLDN6 could promote the expansion of CAR T-cell s and increase their persistence, thus improving the lethality to tumors.<\/span><\/p>\n

According to the newly released data, a total of 22 patients received the treatment, including 13 patients with testicular cancer, 4 patients with ovarian cancer, 1 patient with endometrial cancer, 1 patient with fallopian cancer, 1 patient with sarcoma and 1 patient with gastric cancer, and 1 patient with cancer of unknown origin. Of the 21 assessable cancer patients, the objective remission rate (ORR) was 33%, and the vacancy rate was 67%, of which 1 was in complete remission, 6 in partial remission, and 7 in stable condition. This is similar to the data released at the AACR conference in April, but the effect has declined.<\/span><\/p>\n

It is worth mentioning that the therapeutic effect of this therapy on 7 patients with testicular cancer is encouraging, of which 1 is in complete remission, 3 in partial remission, and 2 in stable condition. The objective remission rate (ORR) was 57% and the disease control rate was 85%.<\/span><\/p>\n

In terms of safety, only one patient had grade 3 cytokine release syndrome and one patient had transient grade 1 neurotoxicity. These two adverse events were resolved quickly. This indicates that CLDN6-CAR-T therapy and combination therapy with CARVac are safe, and only limited and controllable adverse events occur.<\/span><\/p>\n

These data show that CLDN6-CAR-T cell therapy alone and CLDN-CAR-T + CAR-Vac combination therapy are safe and show promising therapeutic effects for CLDN6-positive cancer patients.<\/span><\/p>\n

Prior to this, CLDN6 has not been used as a target for cell therapy, and this clinical trial shows that cell therapy targeted by CLDN6 is more effective in the treatment of solid tumors.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

At the 2022 annual meeting of the American Association for Cancer Research (AACR), BioNTech released its phase 1 clinical data of CAR-T + CARVac in the treatment of Claudin6 (CLDN6) positive solidRead More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":166,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,1],"tags":[27,28,19],"_links":{"self":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/165"}],"collection":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=165"}],"version-history":[{"count":2,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/165\/revisions"}],"predecessor-version":[{"id":168,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/165\/revisions\/168"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/media\/166"}],"wp:attachment":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}